Dishman Carbogen Amcis LtdQ2 FY25
Dishman Carbogen Amcis Ltd Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹173P/E: 23.1Market Cap: ₹3.0K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025).
- →Full-year revenue and profitability expected to increase compared to the previous year; Q2 likely to pick up with integration efforts between Switzerland, India, and France facilities.
- →France facility expects revenue growth to reduce current EBITDA losses over the year.
- →HiPo facility in India (Bavla) is being evaluated for new projects; positive outlook for re-starting operations soon.
- →Soft-gel business and CRAMS in India are expanding, with increasing commercial quantities and market interest in semi-regulated markets.
- →Market focus on U.S., Europe, and Japan, with significant growth potential especially in Japan.
- →No specific quarterly guidance given, but overall growth trajectory and mid- to long-term outlook is positive.
Margin guidance
Category 3- →Revenue and profitability are expected to keep increasing overall, though no specific quarterly guidance is provided due to business nature.
- →Integration efforts between Switzerland, India, and the French facility are ongoing to boost revenue.
- →The French facility, currently making EBITDA losses, is expected to reduce these losses as business increases through the year.
- →Swiss RFPs (requests for proposal) are increasing, indicating growing demand.
- →Japan market share is expected to grow significantly over time.
- →Marketable molecules segment, especially vitamin D analogs and cholesterol business, is expected to see growth in remaining quarters.
- →Debt reduction plans and possible fundraise aim to lower finance costs, potentially improving profitability.
- →CAPEX is lower than expected this year, indicating controlled expenditures.
- →Overall, mid- to long-term view is positive with growth in revenues and profits anticipated.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →Dishman Carbogen Amcis Limited has an enabling resolution in place for a potential fundraise.
- →The company is planning a fundraise, but specific details and timelines are not disclosed yet.
- →The primary intention of the fundraise appears to be debt reduction to lower interest costs.
- →No explicit mention of fresh capital expenditure funding through fundraising at this time.
- →The company is focused on reducing net debt, with a target of reducing debt by at least 10 million Swiss francs in the current year.
- →The first quarter has already seen a substantial reduction in net debt, close to 8 million Swiss francs.
Order book
- →As of June 30, 2025:
- → - Development pipeline: Approximately 117 million Swiss francs.
- → - Commercial order book: Roughly 77 million Swiss francs (for Carbogen Amcis).
- →The order book reflects ongoing healthy demand and robust pipeline for the company’s CDMO business.
- →There is optimistic visibility on increased revenues driven by integration of Swiss, Indian, and French facilities, and ramp-up of the French facility and Swiss RFPs.
- →No specific quarter-wise order book growth guidance is provided due to the business nature, but overall full-year revenue and profitability are expected to improve.
Capex plans
Yes- →Co-investment in new facility in Switzerland with a large Japanese customer focused on ADC products.
- →Japanese customer's investment: 15 million CHF initially; second round investment 25 million CHF, with Dishman contributing internal hours, not cash.
- →Full-year CAPEX guidance reduced to below initial 25 million Swiss francs estimate; Q1 CAPEX was around US$5.6 million (~4 million CHF).
- →Focus on expanding soft gel manufacturing in India (Bavla) targeting semi-regulated markets with growing commercial quantities.
- →Efforts ongoing to restart and generate revenues from the HiPo facility in Bavla, India.
- →Fundraise plans underway with an enabling resolution taken; main aim includes debt reduction to improve financial flexibility.
- →Integration efforts among Switzerland, India, and France aiming to enhance capacity and profitability in upcoming quarters.
How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Dishman Carbogen Amcis Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
Want more stocks like Dishman Carbogen Amcis Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio